DW 5 dextrose in water VF ventricular Fibrillation

FIGURE 9-11. Decision algorithm for resuscitation of VF or pulseless ventricular tachycardia. (CPR, cardiopulmonary resuscitation.) defibrillation attempt should be made after every dose of drug. bEpinephrine should continue to be administered every 3 to 5 minutes throughout the remainder of the resuscitation.

Outcome Evaluation

• Monitor the patient for return of pulse and blood pressure, and for termination of VF and restoration of normal sinus rhythm.

• After successful resuscitation, monitor the patient for adverse effects of drugs administered (Table 9-7).

Torsades de Pointes

Torsades de pointes is a specific polymorphic VT that is associated with prolongation of the QT interval in the sinus beats that precede the arrhythmia.13

Epidemiology and Etiology

The incidence of torsades de pointes in the population at large is unknown. The incidence of torsades de pointes associated with specific drugs ranges from less than 1% to as high as 8% to 10%, depending on dose and plasma concentration of the drug and the presence of other risk factors for the arrhythmia.

Torsades de pointes maybe inherited or acquired. Patients with specific genetic mutations may have an inherited long QT syndrome, in which the QT interval is prolonged, and these patients are at risk for torsades de pointes. Acquired torsades de pointes may be caused by numerous drugs (Table 9-16); the list of drugs that are known to cause torsades de pointes continues to expand.


Torsades de pointes is caused by circumstances, often drugs, that lead to prolongation in the repolarization phase of the ventricular action potential (Fig. 9-2) manifested on the ECG by prolongation of the QT interval. Prolongation of ventricular repolarization occurs via inhibition of efflux of potassium through potassium channels; therefore, drugs that inhibit conductance through potassium channels may cause QT interval prolongation and torsades de pointes.

Table 9-16 Drugs That Have Been Reported to Cause Torsades de Pointes











Chlor pro nwine























1 rl methoprim-sulfa methoxa zo le




Clinical Presentation and Diagnosis of Torsades de Pointes


• As with other tachyarrhythmias, symptoms associated with torsades de pointes are dependent primarily on heart rate and arrhythmia duration, and include palpitations, dizziness, light-headedness, shortness of breath, chest pain (if underlying CAD is present), near-syncope, and syncope

• Torsades de pointes may be hemodynamically unstable if the rate is sufficiently rapid

• Like sustained monomorphic VT, torsades de pointes may result in the absence of a pulse, or may rapidly degenerate into VF, resulting in the syndrome of sudden cardiac death


• Diagnosis of torsades de pointes requires examination of the arrhythmia on ECG

• Torsades de pointes, or "twisting of the points," appears on ECG as apparent twisting of the wide QRS complexes around the isoelectric baseline

• The arrhythmia is associated with heart rates from 140 to 280 bpm

• Characteristic feature: a "long-short" initiating sequence that occurs as a result of a ventricular premature beat followed by a compensatory pause which is followed by the first beat of the torsades de pointes

• Episodes of torsades de pointes may self-terminate, with frequent recurrence

O Prolongation of ventricular repolarization likely promotes the development of early ventricular afterdepolarizations during the relative refractory period, which may provoke re-entry leading to torsades de pointes.

© Drug-induced torsades de pointes rarely occurs in patients without specific risk factors for the arrhythmia (Table 9-17). In most cases, administration of a drug known to cause torsades de pointes is unlikely to cause the arrhythmia; however, the likelihood of the arrhythmia increases markedly in patients with concomitant risk factors.

The onset of torsades de pointes associated with oral drug therapy is somewhat variable and in some cases may be delayed; often, a patient can be taking a drug known to cause torsades de pointes for months or longer without problem until another risk factor for the arrhythmia becomes present, which then may trigger the arrhythmia.

Table 9-17 Risk Factors for Drug-Induced Torsades de Pointes

QTc interval greater than 500 milliseconds

Increase in QTc interval by more than 60 milliseconds compared with the pretreatment value Female sex

Age greater than 65 years Heart failure

Electrolyte abnormalities: hypokalemia and Hypomagnesemia Bradycardia Elevated plasma concentrations of QT interval-prolonging drugs due to drug interactions or absence of dose adjustment for organ dysfunction Rapid IV infusion of torsades-inducing drugs Concomitant administration of more than one agent known to cause QT interval prolongation/torsades de pointes Possible genetic predisposition Previous history of drug-induced torsades de pointes

QTc, corrected QT interval. From Ref. 13.

In some patients, torsades de pointes may be of short duration and may terminate spontaneously. However, torsades de pointes may not terminate on its own, and if

left untreated, may degenerate into VF and result in sudden cardiac death. Several drugs, including terfenadine, astemizole, and cisapride, have been withdrawn from the U.S. market as a result of causing deaths due to torsades de pointes.

Treatment Desired Outcomes

The desired outcomes for treatment include: (a) prevention of torsades de pointes, (b) termination of torsades de pointes, (c) prevention of recurrence, and (d) prevention of sudden cardiac death.

Pharmacologicand Nonpharmacologic Therapy

© In patients with risk factors for torsades de pointes, drugs with the potential to cause QT interval prolongation and torsades de pointes should be avoided or used with extreme caution, and diligent QT interval monitoring should be performed.

Management of drug-induced torsades de pointes includes discontinuation of the potentially causative agent. Patients with hemodynamically unstable torsades de pointes should undergo immediate synchronized DCC. In patients with hemodynamically stable torsades de pointes, electrolyte abnormalities such as hypokalemia and hypomagnesemia should be corrected. Hemodynamically stable torsades de pointes is often treated with IV magnesium, irrespective of whether the patient is hypomag-nesemic; magnesium has been shown to terminate torsades de pointes in normomag-nesemic patients. Magnesium may be administered IV in doses of 1 to 2 g, diluted in 50 to 100 mL 5% dextrose in water (D5W), administered over 5 to 10 minutes; doses maybe repeated to a total of 12 g.

Alternatively, a continuous magnesium infusion may be initiated after the first bolus, at a rate of 0.5 to 1 g/h. Alternative treatments include: transvenous insertion of a temporary pacemaker for overdrive pacing, which shortens the QT interval and may terminate torsades de pointes and reduce the risk of recurrence; IV isoproterenol 2 to 10 mcg/min, to increase the heart rate and shorten the QT interval; IV lidocaine, which may shorten the duration of ventricular repolarization; or IV phenytoin, which may also shorten the duration of ventricular repolarization, administered at a dose of 10 to 15 mg/kg infused at a rate of 25 to 50 mg/min.

Patient Care and Monitoring

1. Perform a thorough medication history to determine whether the patient is receiving any prescription or nonprescription drugs that may cause or contribute to the development of an arrhythmia.

2. Evaluate the patient for the presence of drug-induced diseases, drug allergies, and drug interactions.

3. Determine and monitor the patient's serum electrolyte concentrations to determine the presence or absence of hypokalemia, hyperkalemia, hypomagnesemia, or hy-permagnesemia.

4. Consider the patient's heart rate, blood pressure, and symptoms to determine whether he or she is hemodynamically stable or unstable.

5. Monitor the patient's 12-lead ECG or single rhythm strips to determine if an arrhythmia is present and to identify the specific arrhythmia, and evaluate and monitor the patient's symptoms.

6. Develop drug therapy treatment plans for management of the specific arrhythmia that the patient is experiencing: sinus bradycardia, AV nodal blockade, AF, PSVT, VPDs, VT (including torsades de pointes), or VF.

7. Develop specific drug therapy monitoring plans for the treatment plan implemented. Monitoring includes assessment of symptoms, ECG, adverse effects of drugs, and potential drug interactions.

8. In those receiving warfarin for AF, determine whether the patient's INR is therapeutic.

9. Provide information regarding safe and effective warfarin therapy:

• Notify appropriate clinicians in the event of severe bruising, blood in urine or stool, or frequent nosebleeds.

• Avoid radical changes in diet.

• Do not take nonprescription medications or herbal/alternative/complementary medicines without notifying your physician, pharmacist, and/or health care team members.

10. Stress the importance of adherence to the therapeutic regimen.

11. Provide patient education regarding disease state and drug therapy.

Outcome Evaluation

• Monitor vital signs (heart rate and blood pressure).

• Monitor the ECG to determine the QTc interval (maintain less than 450 milliseconds) and for the presence of torsades de pointes.

• Monitor serum potassium and magnesium concentrations.

• Monitor for symptoms of tachycardia.

Abbreviations Introduced in This Chapter


Atrial fibrillation


Ad cno si ne t riph<?sphat ase






Coronary arLerv disease


Card i ac A rrhy t h m ia Suppre ss U>n 1 riaI


Calcium channel blocker


Card iopul mo n a ry nesu sc i tat io n


Direct current cardioversion


5% Dextrose in water


Emergency department


Heart failure


I nip 1 a n t able e a rd iover tcr- de fib rill ato r


International Normalized Ratio






Left ventricular


Left ventricular ejection fraction


Left ventricular hypertrophy


Mvoc a rd ia ] in fare t io n j


Sod iu m


New York Hcari Association


Paroxysmal sup raven LricuJar tachycardia


Partial thromboplastin time


P remafcu re ven l ric u ] ar con \ rae t io n


Corrected QT Interval


RR interval


Si no atria J


I ransesbphagca 1 ec hoca rd iogra m


Transient ischemic attack


Ventricular pre mal urc bea!


Ven t ríe u la r pre in at u rc co n 1 rat t ion


Vent r ic u lar premat u re depol a r iz at ion


Ventricular fibril Jal ion


Vent r ic u lar l AChyc a I'd i a

Self-assessment questions and answers are available at ht-tp://www. mhpharmacotherapy. com/pp.html.


1. Cummins RO, ed. ACLS Provider Manual. Dallas: American Heart Association, 2006.

2. Paulev PE. Textbook in Medical Physiology and Pathophysiology. Essentials and Clinical Problems. Copenhagen: Copenhagen Medical Publishers, 2000, ht-tp://www.mfi.ku.dk/ppaulev/chapterU/Chapter%201Lhtm.

3. Bazett HC. An analysis of time relationships of the electrocardiogram. Heart 1920;7:353-370.

4. Fogoros RN. Electrophysiologic Testing, 4th ed. Maiden, MA: Blackwell, 2006:17.

5. Vaughan Williams EM. Classification of anti-arrhythmic drugs. In: Sandoe E, Flensted-Jansen E, Olesen KH, eds. Symposium on Cardiac Arrhythmias. Soder-talje, Sweden: AB Astra, 1970:449-472.

6. Singh BN, Vaughan Williams EM. A third class of anti-arrhythmic action. Effects on atrial and ventricular intracellular potentials, and other pharmacological actions on cardiac muscle, of MJ 1999 and AH 3474. Br J Pharmacol 1970;39:675-687.

7. Singh BN, Vaughan Williams EM. A fourth class of anti-arrhythmic action? Effect of verapamil on ouabain toxicity, on atrial and ventricular intracellular potentials, and on other features of cardiac function. Cardiovasc Res 1972;6:109-119.

8. Snyders J, Knoth KM, Roberds SL, Tamkun MM. Time-, voltage-, and state-dependent block by quinidine of a cloned human cardiac potassium channel. Mol Pharmacol 1992;41:322-330.

9. Coraboeuf E, Deroubaix E, Escande D, Coulombe A. Comparative effects of three class I antiarrhythmic drugs on plateau and pacemaker currents of sheep cardiac Purkinje fibres. Cardiovasc Res 1988;22: 375-384.

10. Komeichi K, Tohse N, Nakaya H, et al. Effects of N-acetylprocainamide and sotalol on ion currents in isolated guinea-pig ventricular myocytes. Eur J Pharmacol 1990;187:313-322.

11. Task Force of the Working Group on Arrhythmias of the European Society of Cardiology. The Sicilian gambit. A new approach to the classification of antiarrhythmic drugs based on their actions on arrhythmogenic mechanisms. Circulation 1991;84:1831-1851.

12. Mangrum JM, DiMarco JP. The evaluation and management of bradycardia. N Engl J Med 2000;342: 703-709.

13. Tisdale JE. Arrhythmias. In: Tisdale JE, Miller DM. Drug-Induced Diseases. Prevention, Detection, and Management. Bethesda, MD: American Society of Health-Systems Pharmacists, 2005:289-327.

14. 2005 American Heart Association Guidelines for Cardiopulmonary Resuscitation and Emergency Cardiac Care, Part 7.3. Management of symptomatic bradycardia and tachycardia. Circulation 2005;112: Iv-67-IV-77.

15. Kaushik V, Leon AR, Forrester JS, Trohman RG. Bradyarrhythmias, temporary and permanent pacing. Crit Care Med 2000;28(Suppl):N121-N128.

16. Kannel WB, Wolf PA, Benjamin EJ, Levy D. Prevalence, incidence, prognosis, and predisposing conditions for atrial fibrillation: Population-based estimates. Am J Cardiol 1998;82:2N-9N.

17. Torp-Pedersen C, Moller M, Bloch-Thomsen PE, et al., for the Danish Investigations of Arrhythmia and Mortality on Dofetilide Study Group. Dofetilide in patients with congestive heart failure and left ventricular dysfunction. Danish Investigations of Arrhythmia and Mortality on Dofetilide Study Group. N Engl J Med 1999;341: 857-865.

18. Maisel WH, Stevenson LW. Atrial fibrillation heart failure: Epidemiology, pathophysiology, and rationale for therapy. Am J Cardiol 2003;91:2D-8D.

19. Rich EC, Siebold C, Campion B. Alcohol-related acute atrial fibrillation. A case-control study and review of 40 patients. Arch Intern Med 1985;145:830-833.

20. Black DM, Delmas PD, Eastell R, et al. Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. N Engl J Med 2007;356:1809-1822.

21. Heckbert SR, Li G, Cummings SR, et al. Use of alendronate and risk of incident atrial fibrillation in women. Arch Intern Med 2008;168: 826-831.

22. Haissaguerre M, Jais P, Shah DC, et al. Spontaneous initiation of atrial fibrillation by ectopic beats originating in the pulmonary veins. N Engl J Med 1998;339(10): 659-666.

23. Cohen M, Naccarelli GV. Pathophysiology and disease progression of atrial fibrillation: Importance of achieving and maintaining sinus rhythm. J Cardiovasc Elec-trophysiol 2008;19:885-890.

24. Wijffels MC, Kirchhof CJ, Dorland R, Allessie MA. Atrial fibrillation begets atrial fibrillation. A study in awake chronically instrumented goats. Circulation 1995;92:1954-1968.

25. Fuster V, Ryden LE, Cannom DS, et al. ACC/AH A/ESC 2006 guidelines for the management of patients with atrial fibrillation—Executive summary: A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 Guidelines for the Management of Patients With Atrial Fibrillation). Circulation 2006;114:700-752.

26. Krahn AD, Manfreda J, Tate RB, et al. The natural history of atrial fibrillation: Incidence, risk factors, and prognosis in the Manitoba Follow-Up Study. Am J Med 1995;98:476-484.

27. Elkayam U, Shotan A, Mehra A, Ostrzega E. Calcium channel blockers in heart failure. J Am Coll Cardiol 1993;22(4 Suppl A):139A-144A.

28. Singer DE, Albers GW, Dalen JE, et al. Antithrombotic therapy in atrial fibrillation: American College of Chest Physicians Evidence-Based Practice Guidelines (8th ed). Chest 2008;133:546-592.

29. The Atrial Fibrillation Follow-up Investigation of Rhythm Management (AFFIRM) Investigators. A comparison of rate control and rhythm control in patients with atrial fibrillation. N Engl J Med 2002;347: 1825-1833.

30. Van Gelder IC, Hagens VE, Bosker HA, et al., for the Rate Control versus Electrical Cardioversion for Persistent Atrial Fibrillation Study Group. A comparison of rate control and rhythm control in patients with recurrent persistent atrial fibrillation. N Engl J Med 2002;347: 1834-1840.

31. Carlsson J, Miketic S, Windeler J, et al. Randomized trial of rate-control versus rhythm-control in persistent atrial fibrillation: The Strategies of Treatment of Atrial Fibrillation (STAF) study. J Am Coll Cardiol 2003;41:1690-1696.

32. Opolski G, Torbicki A, Kosior D, et al. Rhythm control versus rate control in patients with persistent atrial fibrillation. Results of the HOT CAFE Polish Study. Kardiol Pol 2003;59:1-16.

33. Gage BF, Waterman AD, Shannon W, Boechler M, Rich MW, Radford MJ. Validation of clinical classification schemes for predicting stroke: Results from the National Registry of Atrial Fibrillation. JAMA 2001;285:2864-2870.

34. Ganz LI, Friedman PL. Supraventricular tachycardia. N Engl J Med 1995;332:162-173.

35. Blomstrom-Lundqvist C, Scheinman MM, Aliot EM, et al., for the Writing Committee to Develop Guidelines for the Management of Patients with Supraventricular Arrhythmias. ACC/AHA/ESC guidelines for the management of patients with supraventricular arrhythmias—Executive summary: A report of the American College of Cardiology/American Heart Association Task Force on practice guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Develop Guidelines for the Management of Patients with Supraventricular Arrhythmias). J Am Coll Cardiol 2003;42:1493-1531.

36. Bikkina M,LarsonMG, Levy D. Prognostic implications of asymptomatic ventricular arrhythmias: The Framingham Heart Study. Am J Cardiol 1994;74:232-235.

37. Lown B, Wolf M. Approaches to sudden death from coronary heart disease. Circulation 1971;44:130-144.

38. Ruberman W, Weinblatt E, Goldberg JD, et al. Ventricular premature beats and mortality after myocardial infarction. N Engl J Med 1977;297:750-757.

39. Echt DS, Liebson PR, Mitchell LB, et al. Mortality and morbidity in patients receiving encainide, flecainide, or placebo. The Cardiac Arrhythmia Suppression Trial. N Engl J Med 1991;324:781-788.

40. The Cardiac Arrhythmia Suppression Trial II Investigators. Effect of the antiarrhythmic agent moricizine on survival after myocardial infarction. N Engl J Med 1992;327:227-233.

41. Teo KK, Yusuf S, Furberg CD. Effects of prophylactic antiarrhythmic drug therapy in acute myocardial infarction. An overview of results from randomized controlled trials. JAMA 1993;270:1589-1595.

42. Chandraratna PA. Comparison of acebutolol with propranolol, quinidine, and placebo: Results of three multicenter arrhythmia trials. Am Heart J 1985;109:1198-1204.

43. Al-Khatib SM, Stebbins AL, Califf RM, et al. Sustained ventricular arrhythmias and mortality among patients with acute myocardial infarction: Results from the GUSTO-III trial. Am Heart J 2003;145:515-521.

44. Stevenson WG, Ellison KE, Sweeney MO, et al. Management of arrhythmias in heart failure. Cardiol Rev 2002;10:8-14.

45. Zipes DP, Camm AJ, Borggrefe M, et al. ACC/AHA/ESC 2006 Guidelines for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: A report of the American College of Cardiology/American Heart Association Task Force and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Develop Guidelines for Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death): Developed in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society. Circulation 2006;114:e385-e484.

46. Gorgels AP, van den Dool A, Hofs A, et al. Comparison of procainamide and lido-caine in terminating sustained monomorphic ventricular tachycardia. Am J Cardiol 1996;78:43-46.

47. Epstein AE, DiMarco JP, Ellenbogen KA, et al. ACC/AHA/HRS 2008 Guidelines for Device-Based Therapy of Cardiac Rhythm Abnormalities: Executive sum mary: A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the ACC/ AHA/NASPE 2002 Guideline Update for Implantation of Cardiac Pacemakers and Antiarrhythmia Devices). Circulation 2008;117:2820-2840.

48. The Antiarrhythmics versus Implantable Defibrillators (AVID) Investigators. A comparison of antiarrhythmic-drug therapy with implantable defibrillators in patients resuscitated from near-fatal ventricular arrhythmias. N Engl J Med 1997;337:1576-1583.

49. Connolly SJ, Gent M, Roberts RS, et al. Canadian implantable defibrillator study (CIDS): A randomized trial of the implantable cardioverter defibrillator against amiodarone. Circulation 2000;101:1297-1302.

50. Connolly SJ, Dorian P, Roberts RS, et al. Comparison of ß-blockers, amiodarone plus ß-blockers, or sotalol for prevention of shocks from implantable cardioverter-defibrillators. The OPTIC study: A randomized trial. JAMA 2006;295:165-171.

51. 2005 American Heart Association Guidelines for Cardiopulmonary Resuscitation and Emergency Cardiac Care, Part 7.2. Management of cardiac arrest. Circulation 2005;112:IV-57-IV-66.

52. Dorian P, Cass D, Schwartz B, et al. Amiodarone as compared with lidocaine for shock-resistant ventricular fibrillation. N Engl J Med 2002;346:884-890.

The Prevention and Treatment of Headaches

The Prevention and Treatment of Headaches

Are Constant Headaches Making Your Life Stressful? Discover Proven Methods For Eliminating Even The Most Powerful Of Headaches, It’s Easier Than You Think… Stop Chronic Migraine Pain and Tension Headaches From Destroying Your Life… Proven steps anyone can take to overcome even the worst chronic head pain…

Get My Free Audio Book

Post a comment